News

Varisolve solves varices in veins
Enlarge image

Clinical TrialsUK

Varisolve solves varices in veins

20.11.2012 - British BTG has reported positive results of pivotal Phase III trials. Its drug Varisolve improved the symptoms of varicose veins in 80% of the cases.

PEM (Polidocanol endovenous microfoam) works in varicose veins, veins that have become enlarged and tortuous. BTG International Ltd., London (UK) announced on 19 November that full data from the two US pivotal Phase III trials VANISH-1 and VANISH-2 support previous positive results on PEM. PEM causes fibrosis inside varicose veins, occluding the lumen of the vessel, and reducing the appearance of the varicosity. BTG sells the compound under the brand name Varisolve. VANISH-2 data, presented at the 26th Annual Congress of the American College of Phlebology in Hollywood, Florida (USA) show that 80% of patients treated with PEM 0.5% or 1.0% dose concentrations, reported an improvement of symptoms compared to 20% in the placebo arm. In addition, 85% of patients demonstrated elimination of saphenofemoral junction reflux and/or occlusion of the great saphenous vein (GSV) and all incompetent veins, compared with 2% in the placebo arm.

Patients varied from young (21) to old (73) and baseline GSV diameters from intermediate (3 mm) to wide (19 mm). Side effects were mostly mild or moderate. Out of 230 PEM-treated patients, 24 experienced thrombi. However, all were small and most (77%) were asymptomatic, and – most importantly – all resolved or stabilised in a median time of 29 days. Also, VANISH-1 results support the efficacy of the polyethylen glycol compound. Here PEM treatment led to an improvement of the appearance of varicose veins as assessed by scrutinising photos of them before and after ultrasound-guided delivery of PEM into the incompetent vein.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/varisolve-solves-varices-in-veins.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • BIOTECH PHARMACON (N)16.80 NOK17.07%
  • ALMIRALL (E)17.26 EUR4.61%
  • EUROFINS SCIENTIFIC (F)301.96 EUR4.16%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • DBV TECHNOLOGIES (F)67.75 EUR-7.57%
  • CO.DON (D)2.50 EUR-7.41%

TOP

  • KARO BIO (S)39.30 SEK2419.2%
  • BIOTECH PHARMACON (N)16.80 NOK78.2%
  • TRANSGENE (F)4.92 EUR75.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-42.7%
  • THROMBOGENICS (B)2.86 EUR-42.3%

TOP

  • KARO BIO (S)39.30 SEK4417.2%
  • ADOCIA (F)82.29 EUR370.5%
  • VERONA PHARMA (UK)5.00 GBP316.7%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-85.7%
  • NEUROVIVE PHARMACEUTICAL AB (S)13.00 SEK-80.0%
  • BIOTEST (D)20.00 EUR-77.0%

No liability assumed, Date: 02.09.2015